News | October 28, 2021
Indian Pharma Market witnesses rise in volumes and prices in September.
Acute therapies continue to report strong growth compared to chronic ones.
Acute therapies continue to report strong growth compared to chronic ones.
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
